HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

EC grants ODD status for Amylyx’s Wolfram syndrome therapy

The HELIOS study assessed the impact of AMX0035 on various functions in adults with Wolfram syndrome. Credit: fernando zhiminaicela from Pixabay. The European Commission (EC)

August 5, 2024

Atypical Teratoid Rhabdoid Tumor drugs in development, 2024

GlobalData tracks 18 drugs in development for Atypical Teratoid Rhabdoid Tumor by 16 companies/universities/institutes. The top development phase for Atypical Teratoid Rhabdoid Tumor is preclinical,

August 31, 2024

Ultra-processed foods raise chronic kidney disease risk, study shows

Consuming ultra-processed foods is linked to an 18% increased risk of chronic kidney disease, with every 10% rise in UPF intake energy contributing to a

April 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.